BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

817 related articles for article (PubMed ID: 28408009)

  • 1. Estimating an EQ-5D-5L Value Set for China.
    Luo N; Liu G; Li M; Guan H; Jin X; Rand-Hendriksen K
    Value Health; 2017 Apr; 20(4):662-669. PubMed ID: 28408009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Less Is More: Cross-Validation Testing of Simplified Nonlinear Regression Model Specifications for EQ-5D-5L Health State Values.
    Rand-Hendriksen K; Ramos-Goñi JM; Augestad LA; Luo N
    Value Health; 2017; 20(7):945-952. PubMed ID: 28712624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores.
    McClure NS; Sayah FA; Xie F; Luo N; Johnson JA
    Value Health; 2017 Apr; 20(4):644-650. PubMed ID: 28408007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valuing Health Using Time Trade-Off and Discrete Choice Experiment Methods: Does Dimension Order Impact on Health State Values?
    Mulhern B; Shah K; Janssen MF; Longworth L; Ibbotson R
    Value Health; 2016; 19(2):210-7. PubMed ID: 27021755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chinese time trade-off values for EQ-5D health states.
    Liu GG; Wu H; Li M; Gao C; Luo N
    Value Health; 2014 Jul; 17(5):597-604. PubMed ID: 25128053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
    Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
    Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L.
    Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL
    Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
    Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
    PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L.
    Hobbins A; Barry L; Kelleher D; Shah K; Devlin N; Goni JMR; O'Neill C
    Pharmacoeconomics; 2018 Nov; 36(11):1345-1353. PubMed ID: 30051267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valuation of Health States Considered to Be Worse Than Death-An Analysis of Composite Time Trade-Off Data From 5 EQ-5D-5L Valuation Studies.
    Gandhi M; Rand K; Luo N
    Value Health; 2019 Mar; 22(3):370-376. PubMed ID: 30832976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dutch Tariff for the Five-Level Version of EQ-5D.
    M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
    Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do Chinese have similar health-state preferences? A comparison of mainland Chinese and Singaporean Chinese.
    Wang P; Li MH; Liu GG; Thumboo J; Luo N
    Eur J Health Econ; 2015 Nov; 16(8):857-63. PubMed ID: 25260384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Health State Sampling Methods on Model Predictions of EQ-5D-5L Values: Small Designs Can Suffice.
    Yang Z; Luo N; Bonsel G; Busschbach J; Stolk E
    Value Health; 2019 Jan; 22(1):38-44. PubMed ID: 30661632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study.
    Sayah FA; Bansback N; Bryan S; Ohinmaa A; Poissant L; Pullenayegum E; Xie F; Johnson JA
    Qual Life Res; 2016 Jul; 25(7):1679-85. PubMed ID: 26659899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
    Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
    Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
    Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
    Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians.
    Welie AG; Gebretekle GB; Stolk E; Mukuria C; Krahn MD; Enquoselassie F; Fenta TG
    Value Health Reg Issues; 2020 Sep; 22():7-14. PubMed ID: 31683254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Test-Retest Reliability of EQ-5D-5L Valuation Techniques: The Composite Time Trade-Off and Discrete Choice Experiments.
    Purba FD; Hunfeld JAM; Timman R; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Passchier J; Busschbach JJV
    Value Health; 2018 Oct; 21(10):1243-1249. PubMed ID: 30314626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which approach is better in eliciting health state utilities from breast cancer patients? Evidence from mainland China.
    Li S; Wang M; Liu L; Chen G
    Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12965. PubMed ID: 30499193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.